Japan Nods Include Torii's Vtama, Skyrizi In New Uses

Concomitant Use Rules Also Revised

Japan issues approval recommendations in new indications, including Torii's Vtama in atopic dermatitis and AbbVie's Skyrizi in ulcerative colitis. Separately, filing requirements for the use of concomitant therapies have been revised.

Japan cautiously eased approval process for concomitant therapeutics used in combination therapy.
Japan cautiously eased approval process for concomitant therapeutics used in combination therapy. • Source: Shutterstock

An advisory committee to Japan’s Ministry of Health, Labour and Welfare (MHLW) has issued approval recommendations for a new batch of drugs including Dermavant Sciences Inc./JT Pharmaceuticals Inc/Torii Pharmaceutical Co. Ltd.’s Aryl hydrocarbon receptor (AhR) Vtama (tapinarof) for psoriasis vulgaris and atopic dermatitis, the latter being the global-first approval in this indication.

Other notable products receiving preliminary nods on 31 May included Novo Nordisk A/S’s Awiqli (once-weekly basal insulin icodec) for diabetes and

More from Japan

Japan Looks To Build Domestic Capacity In New Modalities

 
• By 

Japan's trade ministry is providing new support to build domestic capacity for new modalities including cell and gene therapies, as part of wider efforts to support the national bioventure ecosystem.

Japan Identifies Drugs ‘In Urgent Need’ Of Development

 
• By 

Artesunate for malaria, TB drug pretomanid and omadacycline for pneumonia and skin infections are among the drugs identified by Japanese regulatory authorities in urgent need of domestic development.

Japan Pushes Generic Industry Reforms Via New Govt Fund

 
• By 

Amid ongoing generic drug supply problems, Japan's government is to set up a new fund to support corporate investments geared towards manufacturing and consolidation.

Japan Expands Priority R&D List For Regular Vaccinations

 
• By 

Japan adds four new pediatric vaccines, including for MMRV and norovirus, to a list of priority vaccines eligible for assistance in regulatory processing.

More from Asia